Kaplan Fox NEW YORK, NY - June 20, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
Main Idea: Fulcrum Therapeutics saw its stock drop sharply after the company said it was ending development of its sickle cell disease drug pociredir, and Kaplan Fox & Kilsheimer LLP said it is investigating possible securities law violations.
Key Points:
Patients with sickle cell disease may lose a possible treatment option, and investors can face losses after the stock drop and legal probe.
FDA scrutiny may help protect patients and investors by forcing stronger review of drug safety and company claims.
Rate how each entity in this article affected the American people.
Central company under investigation for potential securities law violations and the main subject of the article.
Law firm announcing and driving the investigation into Fulcrum Therapeutics.
Named regulator whose concerns and conclusions about pociredir are central to Fulcrum Therapeutics’ program discontinuation.
Implicit regulatory context for a securities-violation investigation, though no direct SEC action is reported.
Named drug referenced as part of the FDA’s risk concerns, but it is not an accountable actor.
Distributor/source of the press release content, but not a substantive actor in the story.
Comments here are the same thread shown when this article appears in The Pulse.
No comments on this article yet.
Sign in to comment